Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sergio Waxman

Interventional Cardiology Burlington, MA Medical Doctor

NPI 1720003494 CMS profile 33096

41 Mall Rd, Lahey Clinic, Burlington, MA 01805

Open in the dashboard

General payments

$147,711

450 records reported · program years 2019–2025

Research payments

$9,750

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$105,190 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sergio Waxman of Burlington, MA is reported in the CMS Open Payments database as having received $147,711 across 450 general payments and $9,750 in research payments paid to them. Separately, studies naming them as principal investigator received $105,190 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,977 71
2024 General $7,970 32
2024 Research $3,750 4
2023 General $19,199 77
2023 Research $2,000 2
2022 General $12,414 27
2022 Research $4,000 4
2021 General $27,985 47
2020 General $24,706 65
2019 General $40,459 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sergio Waxman
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sergio Waxman were reported at $14,977. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sergio Waxman Interventional Cardiology median Middle half National median
2019 $40,459 $1,097 $329–$3,048 $163
2020 $24,706 $473 $161–$1,480 $114
2021 $27,985 $677 $233–$1,827 $132
2022 $12,414 $978 $333–$2,724 $149
2023 $19,199 $1,136 $382–$2,986 $160
2024 $7,970 $1,181 $395–$3,326 $164
2025 $14,977 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $57,673 110 payments
  2. Edwards Lifesciences Corporation $16,708 62 payments
  3. BioCardia, Inc. $12,800 2 payments
  4. Medtronic, Inc. $11,704 38 payments
  5. Procyrion, Inc. $9,713 3 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $8,189 9 payments
  7. Surmodics, Inc. $7,150 14 payments
  8. Abbott Laboratories $6,187 39 payments
  9. W. L. Gore & Associates, Inc. $5,360 5 payments
  10. Medtronic Vascular, Inc. $2,983 33 payments
  11. Other $9,244 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $108,657 166 payments
  2. Travel and Lodging $17,344 56 payments
  3. Food and Beverage $12,210 223 payments
  4. Honoraria $9,500 5 payments
Products named General payments · program years 2019–2025
  1. CLINICAL TRIAL PRODUCT Clinical Trial Product $37,361 66 payments
  2. CLINICAL TRIAL PRODUCT Pain Management $13,925 17 payments
  3. RESOLUTE ONYX $9,986 20 payments
  4. AORTIX SYSTEM $9,713 3 payments
  5. LifeVest $8,189 9 payments
  6. SurVeil $7,150 14 payments
  7. GORE CARDIOFORM Septal Occluder $5,360 5 payments
  8. GENERAL STRUCTURAL HEART $3,475 3 payments
  9. CoreValve Evolut $2,586 25 payments
  10. Edwards SAPIEN 3 Transcatheter Heart Valve $2,116 7 payments
  11. Other $22,732 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Surmodics, Inc. $9,750 10 payments

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$23,387

Medicare's payments for the services billed

Medicare patients

87

Average age 75

Services billed

189

51 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Diabetes 63%
Heart failure 51%
Chronic kidney disease 49%
Atrial fibrillation 37%
Arthritis 37%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $17
$17 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $16
$16 — —
ELIQUIS
  • PFIZER INC. $14
$14 — —
NURTEC ODT
  • PFIZER INC. $14
$14 — —
PAXLOVID
  • PFIZER INC. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record